Pharmacovigilance, the industry term for drug safety, was unfamiliar to most of the general public before March 2020. But as the coronavirus pandemic unfolded, its rapid spread thrust drug safety into the spotlight. The public is more aware of drug safety and health regulators’ role than ever — and as the demand for pharmacovigilance information rises, the industry has had to find ways to keep up — according to Beena Wood, VP of safety at ArisGlobal.

A recent CVS Health/Morning Consult survey of Americans age 18+ found that mental health concerns are continuing to rise among individuals of all backgrounds, especially Black, age 65+, young adult, and LGBTQIA+ respondents.

Following the record surge in COVID-19 cases during the Omicron-driven wave, some 58 percent of the U.S. population overall and more than 75 percent of younger children have been infected with the coronavirus since the start of the pandemic, according to a U.S. nationwide blood survey released on April 26.

A national survey by Press Ganey – the leader in healthcare consumer and employee experience – revealed heightened consumer expectations and information needs from pharma brands, presenting a unique opportunity for life sciences companies to drive brand strength.

Psychological stress from the pandemic may be widespread, but those who have had COVID-19 are at much higher risk for new mental health problems than individuals who have managed to avoid the virus, according to a new study. Additionally, researchers have found the BA.2 version of the Omicron variant of the coronavirus – while potentially more transmissible than its BA.1 predecessor – has not led to more hospitalizations or more severe disease in South Africa.

The global project to share COVID-19 vaccines is struggling to place more than 300 million doses in the latest sign the problem with vaccinating the world is now more about demand than supply.

Rare Patient Voice LLC, a leading patient recruitment firm, and MediFind, an advanced digital health platform helping people facing complex health challenges find better care, faster, published a report examining the current state of the diagnostic odyssey for patients with complex diseases during these times of global health issues.

More than one year after the first COVID-19 vaccination was administered in the United States and more than 545 million doses later, new data from a survey conducted online by The Harris Poll among over 2,000 U.S. adults on behalf of Ocugen Inc. show a majority of Americans want more COVID-19 vaccines options to choose from.

In a new white paper, Evidation – which measures health in everyday life – describes best practices for organizations seeking to use PGHD to enhance their clinical product development programs, including real-world examples and case studies.

Read Roberts, director of Key Opinion Leaders (KOL) data solutions at PRECISIONscientia, believes 2022 will see social media platforms as the new method for handling pharma medical education and peer-to-peer communications. So pharma must embrace a new type of digital sleuthing to find KOLs and Digital Opinion Leaders (DOLs), but they must do so carefully and think how to mitigate many risks in this highly regulated market, according to Roberts.